AI Article Synopsis
- The study aimed to determine if taking high-dose atorvastatin before undergoing emergency percutaneous coronary intervention (PCI) could reduce the risk of contrast-induced nephropathy (CIN) in patients with acute ST-segment elevation myocardial infarction (STEMI).
- Patients were randomly assigned to receive either 80 mg of atorvastatin or a placebo before the procedure, with results showing that only 2.6% of the atorvastatin group developed CIN compared to 15.7% in the placebo group (statistically significant).
- Additionally, the atorvastatin group showed better renal function post-procedure, and the results suggest that pretreatment with atorvastatin significantly lowers the risk of developing CIN in these patients.
Article Abstract
Objectives: To investigate whether preprocedural high-dose atorvastatin decreases the incidence of contrast-induced nephropathy (CIN) and protects the renal function after emergency percutaneous coronary intervention (PCI).
Methods: Statin-naive patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing emergency PCI (n = 161) randomly received atorvastatin (80 mg, n = 78, ATOR group) or placebo [n = 83, control (CON) group] followed by long-term atorvastatin (40 mg/day). The primary end point was incidence of CIN.
Results: In the ATOR group, 2.6% of the patients developed CIN versus 15.7% in the CON group (p = 0.01). In the ATOR group, postprocedural serum creatinine was significantly lower (93.4 ± 17.1 vs. 112.6 ± 23.3 µmol/l at 48 h and 84.2 ± 14.2 vs. 95.3 ± 17.7 µmol/l at 72 h, both p < 0.0001) and in the CON group, peak serum cystatin C was lower (0.51 ± 0.14 vs. 0.61 ± 0.13 mg/l, p < 0.0001). Atorvastatin pretreatment was independently associated with a decreased risk of CIN (OR 0.084, 95% CI 0.015-0.462, p = 0.004). The proportion of alanine aminotransferase > 3 × upper limit of the normal value within 1 month was 3.85 versus 1.20% (ATOR vs. CON group, p = 0.57).
Conclusion: Preprocedural high-dose atorvastatin prevents CIN and protects the renal function in patients with acute STEMI undergoing emergency PCI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000339472 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complex dyslipidemia induced by Lorlatinib therapy: A case study.
J Clin Lipidol
October 2024
Section of Nutrition and Metabolic Diseases, Division of Endocrinology, Department of Internal Medicine and the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Context: Lorlatinib is an anaplastic lymphoma kinase (ALK) inhibitor, which is currently used for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Previous reports have noticed an association between lorlatinib and hyperlipidemia, however the specific mechanisms for this side effect remain unknown. Some investigators have reported nephrotic syndrome to be the underlying cause of lorlatinib-induced hyperlipidemia.
View Article and Find Full Text PDFEfficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention.
J Cardiothorac Surg
October 2024
Department of Cardiology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, 215101, Jiangsu Province, China.
Background: At present, the clinical methods for preventing and treating contrast-induced nephropathy (CIN) are limited, and statins can play a better role during this process. So, we aimed to assess the atorvastatin on renal function in nephropathy patients after percutaneous coronary intervention (PCI).
Methods: In this work, 100 elderly patients with coronary heart disease (CHD) were selected into an experimental group (Exp group, 50 cases, 40 mg/d po atorvastatin) and a control group (Ctrl group, 50 cases, 10 mg/d po atorvastatin).
Evaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon.
BMC Cardiovasc Disord
September 2024
Department of Community Medicine, School of Medicine, Farshchian Cardiovascular Subspecialty Medical Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Article Synopsis
- Coronary Slow Flow Phenomenon (CSFP) is a condition where coronary arteries show delayed blood flow even though they appear normal in angiograms; this study aimed to assess the impact of atorvastatin on left ventricular (LV) strain in CSFP patients.
- The study involved 51 patients receiving 40 mg of atorvastatin daily for eight weeks, with left ventricular function measured using echocardiograms before and after treatment.
- Results showed significant improvements in LV strain and function after atorvastatin treatment, but it did not significantly affect right ventricular function or pulmonary artery pressure.
High-dose atorvastatin and rosuvastatin reduce the levels of neutrophil extracellular trap-related proteins in coronary artery disease: association with prothrombotic state.
Pol Arch Intern Med
October 2024
Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; Krakow Center for Medical Research and Technologies, St. John Paul II Hospital, Kraków, Poland.
Article Synopsis
- The study aimed to investigate how high-dose statins impact the formation of neutrophil extracellular traps (NETs) in patients with coronary artery disease (CAD).
- A group of 130 patients was monitored before and after starting statin therapy, revealing significant reductions in proteins linked to NETs, such as citrullinated histone H3, myeloperoxidase, and neutrophil elastase.
- These reductions correlated with decreased inflammation markers and changes that suggest improved clot formation properties, indicating that statins may have beneficial effects beyond just lowering LDL cholesterol.
This article aims to investigate the effect of Zhuyu Pills on atherosclerosis(AS) and decipher the underlying mechanism. The mouse model of AS was established by feeding with a high-fat diet for 12 weeks. The 50 successfully modeled mice with the apolipoprotein E knockout(ApoE~(-/-)) were assigned by the random number table method into 5 groups(n=10): model, low-, medium-, and high-dose(130.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!